Peripheral T-Cell Lymphoma

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

ALK
ALK Alternative Transcription Site
ALK Amplification
ALK Expression
ALK Fusion
ALK Mutation
BCL6 Expression
CD4 Expression
CD52 Expression
CXCL13 Expression
ICOS Expression
MME Expression
MYC
MYC Expression
MYC Fusion
MYC Mutation
MYC Overexpression
MYCN
MYCN Amplification
PDCD1 Expression

TNFRSF8 Expression

Overview

Clinical Trials

View Clinical Trials for Peripheral T-Cell Lymphoma

There are 51 clinical trials for peripheral T-cell lymphoma, of which 43 are open and 8 are completed or closed. Of the trials that contain peripheral T-cell lymphoma as an inclusion criterion, 1 is early phase 1 (1 open), 20 are phase 1 (13 open), 8 are phase 1/phase 2 (8 open), 19 are phase 2 (18 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open).

TNFRSF8, ALK, and BCL6 are the most frequent gene inclusion criteria for peripheral T-cell lymphoma clinical trials [3].

Trials Investigating Peripheral T-Cell Lymphoma by Gene and Recruiting Status

Romidepsin, brentuximab vedotin, and cyclophosphamide are the most common interventions in peripheral T-cell lymphoma clinical trials.

Drugs Being Investigated in Peripheral T-Cell Lymphoma Trials by Recruiting Status

Significant Genes in Peripheral T-Cell Lymphoma

ABL1 +

ABL1 is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ABL1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

AFF1 +

AFF1 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains AFF1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ASXL1 +

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ASXL1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

BCL2 +

BCL2 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCL2 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BCL6 +

BCL6 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BCR +

BCR is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BCR status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

BIRC2 +

BIRC2 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC2 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BIRC3 +

BIRC3 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CARD11 +

CARD11 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CARD11 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD274 +

CD274 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CD79A +

CD79A is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79A status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79B +

CD79B is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

DEK +

DEK is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain DEK status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

ELL +

ELL is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ELL status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FLT3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

HRAS +

HRAS is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

IRAK1 +

IRAK1 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IRAK1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

JAK2 +

JAK2 is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain JAK2 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

JAK3 +

JAK3 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains JAK3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2A +

KMT2A is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KMT2A status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

KRAS +

KRAS is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

MECOM +

MECOM is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MECOM status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT10 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MLLT4 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYC +

MYC is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYCN +

MYCN is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYCN status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYD88 +

MYD88 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYD88 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NFKBIA +

NFKBIA is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NFKBIA status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS +

NRAS is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

NRIP3 +

NRIP3 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains NRIP3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NUP214 +

NUP214 is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain NUP214 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

PBX1 +

PBX1 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PBX1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RPN1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

RUNX1 +

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RUNX1 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

TCF3 +

TCF3 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TNFAIP3 +

TNFAIP3 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TNFAIP3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 +

TP53 is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain TP53 status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (0 open) [3].

TYK2 +

TYK2 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TYK2 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

Disease Details

Parent(s)

Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.